Home
Live Updates
Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups : comparemela.com
Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups
Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.
Related Keywords
Perez Valderrama ,
Michiels Van ,
Bristol Myers Squibb ,
Astellas Pharma ,
Novartis ,
Gilead Sciences ,
Cancers Symposium ,
Der Heijden ,
Enfortumab Vedotin ,
Pembrolizumab ,
Padcev ,
Keytruda ,
Asco Gu ,
Genitourinary Cancers Symposium ,
Ev 302 ,
Keynote A39 Trial ,
Michiels Van Der Heijden ,
D ,
Phd ,
Netherlands Cancer Institute ,
Subgroup Analysis ,
Urothelial Carcinoma ,
comparemela.com © 2020. All Rights Reserved.